**Supplementary Figure S2.** Kaplan–Meier curves for progression-free survival in the intention-to-treat population (Panel A); among patients with tumors that were positive for the programmed death 1 ligand (PD-L1) (Panel B) and among patients with PD-L1–negative tumors (Panel C). HR=0.42; 99.5% CI, 0.31 to 0.57; for comparing the nivolumab-plus-ipilimumab group to the ipilimumab group (P<0.001) and HR= 0.57; 99.5% CI, 0.43 to 0.76; P<0.001 in the comparison of nivolumab group to the ipilimumab group. From ref. 1: Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34. © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

